Why Aura Biosciences, Inc.’s (AURA) Stock Is Up 8.69%
As of Thursday, July 02, Aura Biosciences, Inc.’s AURA share price has surged by 8.69%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company’s proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Commentary & Analysis
Why Aura Biosciences, Inc.’s (AURA) Stock Is Down 7.19%
As of Wednesday, May 06, Aura Biosciences, Inc.’s AURA share price has dipped by 7.19%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Aura Biosciences, Inc.’s (AURA) Stock Is Up 5.51%
As of Tuesday, May 05, Aura Biosciences, Inc.’s AURA share price has surged by 5.51%, which has investors questioning if this is right time to sell.Michael Rose
Why Aura Biosciences, Inc.’s (AURA) Stock Is Up 12.40%
As of Tuesday, May 05, Aura Biosciences, Inc.’s AURA share price has surged by 12.40%, which has investors questioning if this is right time to sell.Tudor Pop
Why Aura Biosciences, Inc.’s (AURA) Stock Is Up 12.71%
As of Monday, May 04, Aura Biosciences, Inc.’s AURA share price has surged by 12.71%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | AURA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $773.2 | $252.6 | 42% |
|
| Shares Out (Mil) | 67.4 | 52.3 | 55% |
|
| Institutional Ownership | 97.5% | 92.1% | 74% |
|
| Float (Mil) | 99.5 | 40.2 | 61% |
|
| Beta | 0.37 | 0.95 | 21% |
|
| Avg Daily Volume (000s) | 346 | 455 | 53% |
|
| Price Change (52-week) |
6.4% | 52.9% | 50% |
|
| Growth | AURA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (36.8%) | (9.9%) | 10% |
|
| EPS (5yr) | 53.6% | 16.0% | 94 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 15.0% | (15.6%) | 73% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | AURA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($112) | ($43) | 10% |
|
| EPS (TTM) | ($1.738) | ($1.600) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | ($91) | ($31) | 6% |
|
| Net Cash Flow (TTM) (Mil) | $47 | $5 | 70% |
|
| Long-Term Debt (Q1) (Mil) | $14 | $5 | 30% |
|
| Enterprise Value (Q1) (Mil) | $722 | $180 | 38% |
|
| Valuation | AURA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.20 | 2.56 | 74% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | AURA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (76.7%) | (49.8%) | 7% |
|
| ROE | (95.6%) | (55.5%) | 10% |
|
| Liabilities to Assets | 22.1% | 30.3% | 14% |
|
| F-Score | 1 | 3 | 1% |
|
Aura Biosciences, Inc. did not pass any screens on 7/31/2026.
